Key Insights

Highlights

Treatment Research

3 treatments under study, led by Biological Study On Circulating Tumor Dna Optional For The Patient

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06762405Phase 3RecruitingPrimary

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Showing all 1 trials

Research Network

Common Treatments

  • Biological Study On Circulating Tumor Dna Optional For The Patient1
  • Dostarlimab1
  • Radiotherapy1

Active Sponsors

  • Centre Hospitalier Universitaire Dijon1
  • Centre Hospitalier Universitaire De Dijon1

Related Conditions

  • Rectal Cancer Locally Advanced With Microsatellite Unstable Or Mismatch Repairdeficient1

Activity Timeline